Defensive sectors have beaten the S&P 500 by a wide margin in recent months, even though they are priced much higher relative to earnings estimates than the index.
Eurizon Capital SGR S.p.A. raised its stake in shares of Edwards Lifesciences Corporation (NYSE: EW) by 19.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 224,884 shares of the medical research company's stock after purchasing an
Candriam S.C.A. reduced its holdings in Edwards Lifesciences Corporation (NYSE: EW) by 44.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 370,875 shares of the medical research company's stock after selling 292,909 shares during the quarter. Candriam S.C.A. owned about 0.06%
Edwards Lifesciences NYSE: EW raised its 2026 sales and earnings guidance after third-quarter results exceeded management's expectations, with growth across its heart-valve businesses and regions.
Wall Street analysts shifted their stances on some of the market's most closely watched names Wednesday, with surprising cuts hitting stocks many investors still consider safe bets and fresh upgrades landing on names that have struggled all year.
Heavy AI capex hit free cash flows at Alphabet and Meta, while Microsoft and Amazon faced mounting concerns over compressed margins, search cannibalization, and agentic commerce disruption. With Apple reporting on an unusual Monday schedule, nine S&P 500 firms confirmed delayed reporting dates, a historical indicator of potential bad news ahead. This marks the second week of Q3 earnings season, with 2,465 companies expected to report and overall S&P 500 EPS growth holding at a robust 29.5%.